Abstract: Despite the availability of two attenuated vaccines, rotavirus (RV) gastroenteritis remains an important cause of mortality among children in developing countries causing about 215,000 infant deaths annually. Currently, there are no specific antiviral therapies available. RV is a non-enveloped virus with a segmented double-stranded RNA genome. Viral genome replication and assembly of transcriptionally active double-layered particles (DLPs) take place in cytoplasmic viral structures called viroplasms. In this study, we describe strong impairment of the early stages of RV replication induced by a small molecule known as RNA polymerase III inhibitor, ML-60218 (ML). This compound was found to disrupt already assembled viroplasms and hamper the formation of new ones without the need of de novo transcription of cellular RNAs. This phenotype correlated with reduction in accumulated viral proteins and newly made viral genome segments, disappearance of the hyperphosphorylated isoforms of the viroplasm-resident protein NSP5 and inhibition of infectious progeny virus production. In in vitro transcription assays with purified DLPs, ML showed a dose-dependent inhibitory activity indicating the viral nature of its target. ML was found to interfere with the formation of higher order structures of VP6, the protein forming the DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-treated DLPs showed a dose-dependent structural damage. Our data suggest that interactions between VP6 trimers are essential not only for DLP stability but also for the structural integrity of viroplasms in infected cells.IMPORTANCE Rotavirus gastroenteritis is responsible for a large number of infant deaths in developing countries. Unfortunately, in those countries where effective vaccines are urgently needed, the efficacy of the available vaccines is particularly low. Therefore, the development of antivirals is an important goal, as they might complement the available vaccines or represent an alternative option. Moreover, they may be decisive in fighting the acute phase of infection. This work describes the inhibitory effect on rotavirus replication of a small molecule initially reported as an RNA polymerase III inhibitor. The molecule is the first chemical compound identified able to disrupt viroplasms, the viral replication machinery, and to compromise the stability of DLPs by targeting the viral protein VP6. This molecule thus represents a starting point towards the development of more potent and less cytotoxic compounds against rotavirus infection. showed a dose-dependent inhibitory activity indicating the viral nature of its target. ML was 38 found to interfere with the formation of higher order structures of VP6, the protein forming the 39 DLP outer layer, without compromising its ability to trimerize. Electron microscopy of ML-40 treated DLPs showed a dose-dependent structural damage. Our data suggest that 41 interactions between VP6 trimers are essential not only for DLP stability but also for the 42 structural integrity of viroplasms in infected cells. 
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ML impairs viroplasm formation and disrupts already assembled viroplasms. Treatment 102
of RV-infected cells with ML at 10 μM caused a strong reduction of viroplasms accumulated 103 during viral replication and, in the case of the porcine OSU strain, a complete disappearance 104 of those structures, as observed by both immunofluorescence (Fig. 1) and electron 105 microscopy analysis (Fig. 2) . Independently of whether the compound was added at 1, 3 or 5 106 hours post-infection (hpi), a 4 h treatment had the same effect on viroplasms (Fig. 1A) . 107
Viroplasm disruption correlated with a decrease of accumulated viral proteins, as observed 108 with the porcine OSU and the simian SA11 strains (Fig. 1B) . When added before infection, 109 together with the infectious virion, or at 1 hpi (Fig. 1C , upper panel), ML caused a reduction of 110 viral proteins in a dose-dependent manner with a concomitant disappearance of the NSP5 111 hyperphosphorylated isoforms (Fig. 1C, middle panel) . ML added at the concentration of 10 112 μM together with the infectious virions completely blocked assembly of viroplasms (Fig. 1C,  113 bottom panel). The same phenotype was observed in two different cell lines (monkey kidney 114 epithelial MA104 cells and human osteosarcoma U2OS cells) upon infection with two different 115 RV strains (OSU and SA11) ( Fig. 1D and E) . 116
The absence of viroplasms and the reduction of accumulated viral proteins indicate 117 that ML inhibits RV replication. This result was confirmed assessing the yield of infectious 118 progeny virus produced at different time points post-infection (Fig. 1F ) and the production of 119 6 newly made dsRNA genome segments (gs) (Fig. 1G) . During the time intervals of the 120 analysis, ML was not cytotoxic (Fig. 1H) . 121
Three hours was the minimum time and 10 μM the minimal concentration required for 122 complete effect on viroplasms (data not shown). Concentrations higher than 20 μM were toxic 123 for cells, as shown by the decreased levels of actin in Western blots (Fig. 1C) . Treatments of 124 up to 12-14 h at 10 μM were well tolerated (Fig. 1H) . 125
ML-mediated viroplasm disruption causes NSP5 dephosphorylation. In order to 126
determine whether the effect of ML on NSP5 phosphorylation was due to activation of 127 phosphatases, 0.5 μM okadaic acid (an inhibitor of serine/threonine phosphatases) was 128 added to OSU-infected cells at 3 hpi (1 h before the addition of ML), and maintained during 129 the following 4 h treatment (see scheme in Fig. 3 ). Upon inhibition of phosphatases with 130 okadaic acid, the effect of ML on viroplasms remained unaltered (Fig. 3 , bottom right panel) 131 but NSP5 hyperphosphorylated isoforms did not disappear (Fig. 3, lane 2) . This result 132
suggests that the effect of ML on viroplasms is not mediated by activation of phosphatases 133
and that NSP5 dephosphorylation is the consequence of disruption of viroplasms which, when 134 intact, protect NSP5 from cytosolic phosphatases. 135
ML activity against RV does not require newly synthesized cellular transcripts or 136
proteins and is independent of the RNA polymerase III catalytic activity. To determine 137 whether the phenotype observed under ML treatment was due to de novo synthesis of cellular 138 proteins or RNAs, actinomycin D was added to cells at 3 h post-infection, one hour before 139 treatment with the drug, and maintained during the following 4 h treatment (see scheme in 140 Fig. 4A ). Actinomycin D is a DNA intercalator that inhibits transcription of RNA polymerase I 141 at very low concentrations (>0.01 μg/ml), of RNA polymerase II at concentrations higher than 142 7 synthesized RNAs were labeled with the ribonucleoside homolog 5-ethynyl uridine (EU) and 144 visualized by reacting with an Alexa-488 conjugated azide (green) (Fig. 4A, right panel) to 145 assess the effectiveness of actinomycin D treatment. Actinomycin D at 10 μg/ml did not 146
interfere with the effect of ML indicating that newly synthesized cellular transcripts are not 147 required for ML antiviral activity. Also, in the absence of ML, treatment with actinomycin D did 148 not compromise viroplasm integrity nor affected the accumulation of viral proteins (Fig. 4A,  149 left panel). On the contrary, it slightly increased the amounts of VP2 and NSP5 compared to 150 the untreated control ( 3). All these data indicate that RV replication does not require the catalytic activity of RNA 153 polymerase III and that ML activity against RV is not mediated by inhibition of this cellular 154 target. In addition, de novo protein synthesis is not required for ML activity. Addition of ML (at 155 4 hpi) to cells treated with the protein synthesis inhibitor cycloheximide (CHX) (added at 3 hpi) 156 still caused viroplasm disruption and NSP5 dephosphorylation (Fig. 4B) . 157 ML compromises DLPs stability. We then investigated whether ML acts on a viral target. 158 RV DLPs were purified from cells infected with OSU or SA11 strains, and their transcriptional 159 activity tested in vitro in the presence of increasing ML concentrations. An irrelevant small 160 molecule (compound #7749832, ChemBridge Corp.) solubilized in the same buffer was used 161 as a control. Upon incubation with ML, the number of transcripts produced by DLPs of both 162 strains was significantly decreased in a dose-dependent manner (Fig. 5A ) as compared to the 163 vehicle or the irrelevant small molecule. An IC 50 of 10 μM was observed for both viruses. In 164 order to be transcriptionally active, DLPs must be intact. The sole absence of the external 165 layer formed by VP6 trimers is sufficient to compromise the transcriptional activity (3, 4, 21). We thus investigated whether ML impaired the interaction of VP6 with VP2 or with itself, as in 176 the formation of trimers or in the interactions between trimers. 177
The VP6-VP2 interaction was tested by co-immunoprecipitation with an anti-VP6 178 monoclonal antibody (clone RV-138) from cells overexpressing both VP6 and VP2 and 179 treated for 5 h with ML. The inhibitor was also maintained during cell lysis and incubation with 180 the precipitating antibody. The experiment, repeated at various ML concentrations (up to the 181 highest concentration used of 200 μM), showed that ML did not interfere with VP6-VP2 182 interactions (Fig. 6A) . 183 VP6 trimer formation was assessed by Western blots of non-boiled lysates from cells 184 overexpressing VP6 and treated with ML. In fact, VP6 trimers (MW = 135 kDa) resist SDS 185 denaturing and reducing conditions but not high temperatures (23). Cells infected with a 186 recombinant vaccinia virus expressing VP6 (vvVP6) were treated with ML at 1 hpi for 7 h. 187 VP6 trimers formed in vivo were not affected by the presence of ML (Fig. 6B, left panel) , 188 which did not compromise the total levels of VP6 expression. Intact VP6 trimers were also 189 found in RV-infected cells treated with ML, although in decreased amounts because of the 190 reduced viral replication (Fig. 6B, right panel) . ML, however, appears to interfere with the 191 9 formation of VP6 higher order structures typically observed in cells overexpressing VP6 in the 192 absence of other RV proteins (24) (Fig. 6C) . In immunofluorescence, VP6 staining showed 193 tubular structures or aggregates, while in the presence of ML it showed homogenous 194 distribution (Fig. 6C) . In contrast, other structures such as viroplasm-like structures (VLS) 195 generated by overexpression of NSP5 with NSP2 (VLS-NSP2i) or with VP2 (VLS-VP2i) (24, 196 25) or with both, were not affected by ML treatment (Fig. 7A, C) . Under these conditions, 197
NSP5 remained hyperphosphorylated and VP6 recruitment into VLS was not compromised 198
Depending on pH and ionic strength, purified VP6 self-assembles into helical tubes or 200 spherical particles ( (26) on the assembly of these VP6 structures, we performed a negative staining electron 205 microscopy analysis on purified VP6 in the presence or absence of ML. Upon incubation with 206 25 µM ML, both VP6 tubes (pH 6.0) and spherical particles (pH 4.0) were severely damaged 207 (Fig. 6D) . In fact, a thorough visual inspection of the EM grids failed to reveal any intact tube 208 or sphere in the presence of ML (Fig. 6D , right panels). Thus, ML has a direct effect on the 209 higher order interactions of VP6 trimers. 210
To further study the effect of ML on VP6, the interaction between the protein and the 211 drug was evaluated in nanoscale thermophoresis assays. Upon addition of the inhibitor, a 212 concentration-dependent quenching of the labeled protein was observed, which allowed us to 213 calculate an EC 50 value of 294  62 µM (Fig. 6E ). Since millimolar concentrations of divalent 214 cations are known to destabilize the VP6 higher order structures shifting the equilibrium 215 10 toward isolated trimers (26), thermophoresis mobility was also tested in the presence of CaCl 2 216 (up to 500 mM). No significant changes were observed (data not shown). Thus, in the 217 thermophoresis experimental conditions, the signal observed was due to direct binding of ML 218 to VP6 trimers, rather than to a destabilization of its oligomerization state. Altogether, these 219 results suggest that, although ML binds VP6 trimers with moderate affinity, it likely prevents 220 the optimal packing of its higher oligomeric structures on the DLP outer layer. Whether this is 221 due to a conformational change induced by the molecule or to a steric hindrance effect is not 222 known and awaits structural confirmation. 223
The effect of ML on viroplasms and VP6 strongly indicates that VP6 plays an essential 224 role in the structural integrity of viroplasms. In fact, as already reported (5), silencing VP6 225 expression with a specific siRNA led to a significant reduction of viroplasm number in RV-226 infected cells (Fig. 8A ), strengthening the hypothesis that VP6 is essential for maintaining the 227 structure of viroplasms. Of note, in ML-treated virus-infected cells VP6 was found diffused 228 throughout the cytosol (Fig. 8B) . 229
230

DISCUSSION 231
We describe for the first time a compound able to disrupt already formed RV 232 viroplasms in infected cells, thus impairing RV replication as demonstrated by the decrease in 233 viral protein translation, de novo synthesis of viral genomic dsRNA and yield of progeny virus. 234
This effect of ML on RV replication was initially surprising because this drug, a cell-235 permeating indazole-sulfonamide small molecule, has been described to favor replication of 236 some DNA viruses and bacteria by inhibiting the RNA polymerase III-mediated mechanism 237 that activates the RIG-I pathway (28-30). RV, however, is an RNA virus. We ruled out that ML 238 inhibition was mediated by RNA polymerase III activity as actinomycin D, used at a 239 11 concentration that inhibits RNA polymerase III transcription, still allowed RV replication. In 240 addition, actinomycin D was unable to counteract the ML antiviral effect, indicating that ML 241 antiviral activity does not require synthesis of newly made cellular transcripts, including those 242 of RNA polymerase III. This is consistent with the finding that the ML target is of viral nature. 243
We showed that ML impaired DLP stability in vitro by inhibiting the interactions between VP6 244 trimers. In the absence of a correctly assembled VP6 layer, DLPs lose the capacity to 245 transcribe plus-stranded RNAs (3, 31). These results explain the decreased amount of 246 transcripts obtained in vitro from purified DLPs and provide the basis for the reduced amounts 247 of viral proteins and dsRNAs observed in infected cells treated with ML. Altogether these data 248 indicate that the inhibitor binds VP6, compromising both the integrity of DLPs and the 249 structure of viroplasms. 250
The mechanism of viroplasm assembly is still not well understood. Viroplasms contain 251 six viral proteins: two non-structural, NSP5 and NSP2 (both shown to be essentially required 252 for viroplasm formation (6, 7, 32)), and four structural proteins, VP1, VP2, VP3 and VP6 (33). 253
Electron microscopy studies suggested that newly made DLPs assemble at the periphery of 254 viroplasms (34). Immunogold labeling of VP6 indicated that this protein localizes exclusively 255 at the periphery of viroplasms, while NSP5, NSP2, and VP2 were also detected in the 256 viroplasm interior (Arnoldi et al., unpublished results). Silencing VP6 expression leads to 257 fewer and smaller viroplasms and reduced amounts of viral mRNAs, viral dsRNAs and viral 258 proteins (5), indicating that this protein is also required for the structural and functional 259 integrity of viroplasms. We confirmed that knocking down VP6 expression produced a sharp 260 reduction in the number of viroplasms ( remains obscure, it was hypothesized that the effect was the consequence of blocking 302 proteasome-mediated degradation of an unknown host factor capable of impairing formation 303 of viroplasms (16, 37) . Regarding MT-depolymerizing drugs and Eg5 kinesin inhibitor, they 304 both destabilize the viroplasm structure and their coalescence but do not reduce viral proteins 305 expression (17). Finally, treatment with thiazolides causes a reduction in the viroplasm size, 306 resulting in an inhibition of the dsRNA genome segments synthesis, but without impairing viral 307 protein expression or affecting stability of RV particles (18). Importantly, the compound 308 described in this work is the only RV inhibitor so far identified that can disrupt viroplasms and 309 acts on a viral target. This makes the chemical structure of ML particularly appealing for 310 14 further studies in the field of antivirals. As such, ML could not be used as an antiviral drug, 311 because of its cytotoxicity. However, future research and structural analyses might lead to the 312 development of more potent and selective inhibitors as potential drugs against RV infections. 313 (1:1,500) (kindly provided by S. López), anti-NSP4 rabbit serum (1:1,1000) (kindly provided 393 by D. Luque), anti-VP5 clone 2G4 mouse monoclonal antibody (1:2,000) (kindly provided by 394 H. Greenberg), anti-alpha-tubulin mouse monoclonal antibody (1:3,000, Calbiochem), anti-395 actin rabbit polyclonal antibody (1:1,000, Sigma). The membranes were then incubated with 396 the corresponding HRP-conjugated goat anti-guinea pig (1:10,000, Jackson 397 ImmunoResearch), goat anti-mouse (1:5,000, Jackson ImmunoResearch), goat anti-rabbit 398
314
MATERIALS AND METHODS 315
Cells and viruses. MA104 cells (embryonic
(1:5,000, Thermo Scientific Pierce) secondary antibodies. Signals were detected by using the 399 enhanced chemiluminescence system (Pierce ECL Western Blotting Substrate, Thermo 400
Scientific). 401
Immunofluorescence microscopy. Immunofluorescence experiments were performed as 402 described previously (49) using the following antibody dilutions: anti-NSP5 guinea pig serum 403 1:1,000; anti-VP6 mouse monoclonal antibody (clone 4B2D2) 1:1,000 (kindly provided by J. L. Technologies). Samples were analyzed by confocal microscopy (Zeiss LSM510 equipped 412 with a 100x NA 1.3 objective), and images were processed using LSM Image Examiner 4.0 413
Software. 414
Analysis of RV genome segments. Total RNA was purified from MA104 cells infected with 415 OSU (MOI; 25 VFU/cell) after treatment with 10 μM ML or a control vehicle (dimethyl 416 sulfoxide, DMSO) from 1 to 6 hpi. Crude viral preparations were digested with 10 μg/ml of 417 proteinase K (Thermo Fisher Scientific) in the presence of 5 mM EDTA and 0.5% SDS, for 30 418 min at 60°C. RNA was then purified by phenol-chloroform extraction and precipitation with 5M 419 ammonium acetate and quantified using the NanoDrop 1000 Spectrophotometer (Thermo 420 Fisher Scientific). 3.5 μg of total RNA were separated by Tris-glycine nondenaturing 421 polyacrylamide (4% stacking gel, 10% resolving gel) and transferred to a charged nylon 422 membrane (GeneScreen Plus Hybridization Transfer Membrane, Perkin Elmer). The 423 membrane was blocked with 5% milk and 50 μg/ml DNA fish sperm (Affymetrix) in PBS and 424 was incubated overnight with the mouse anti-dsRNA (clone J2) monoclonal antibody (1:1,000; 425 English and Scientific Consulting Bt., Hungary) (50), followed by reaction with HRP-426 conjugated goat anti-mouse antibody (1:5,000, Jackson ImmunoResearch). (17). At 1 hpi, 20 µM ML was added. At 6 hpi, cells were fixed with 2.5% glutaraldehyde in 468 100 mM Na/K-phosphate buffer, pH 7.4 for 1 h at 4˚C and kept in 100 mM Na/K-phosphate 469 buffer overnight at 4˚C. Afterwards, samples were post-fixed in 1% osmium tetroxide in 100 470 mM Na/K-phosphate buffer for 1 h at 4˚C, dehydrated in a graded ethanol series starting at 471 
